You are here
GMSI Award 2015 – Molecular markers of multiple sclerosis disease progression
Gabriele de Luca
This lecture was given at the Grant for Multiple Sclerosis Innovation Awards Event, 8th October 2015. The GMSI award was supported by Merck KGaA, Darmstadt, Germany. Dr. de Luca is an award winner and works at the University of Oxford, UK.
Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase. In most patients this was an unrelenting spinal cord syndrome with significant neuronal loss and axonal loss as a substrate for this disability.
The predominant genetic risk factor for multiple sclerosis was the HLA-DRB1*15 allele, which influenced the extent of spinal cord disability. This was important for the presentation of antigens and could alter the phenotypic expression of this disease. In patients positive for this allele, the extent of demyelination was significantly greater, both within plaques and within normal white and grey matter.
In an attempt to understand these differences, Dr. de Luca and his colleagues planned detailed surveys of the proteome (the sum of all the proteins) and the metabolome (the sum of all small molecules) for CSF and spinal cord material from multiple sclerosis patients and controls. Cervical and lumbar cord samples would be compared for each case, with lesional and non-lesional samples for comparison. The top candidates would be examined and related to axonal loss, demyelination and progression.
Dr. de Luca considered that this should provide a unique opportunity to correlate quantitative SC neuropathology with proteomic and small molecule signatures. It could shed light on the pathogenesis of MS spinal cord pathology and therefore disease progression.
Gabriele de Luca11/17/2015 - 14:03Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.
GMSI Award 2015 – Driving microglia metabolism towards remyelination and restoration of brain damage in multiple sclerosis
Claudia Verderio11/17/2015 - 13:53According to Dr. Verderio, the new proposal stemmed from data on the biological activity of vesicles from microglia cells, on the proliferation, differentiation and myelination of oligodendrocyte precursor cells (OPCs).
Laura Airas11/17/2015 - 13:40In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
Elga de Vries11/17/2015 - 13:31Microglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.
David Bates11/09/2015 - 11:00Professor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Steven Hildemann11/09/2015 - 10:49Merck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
David Bates11/09/2015 - 10:41Professor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology...